BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.

Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.

Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.

Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.

Alcatraz's April 2026 round reflects growing demand for privacy-aware biometric access systems in critical facilities.

April 2026 VC funding roundup with NYC and U.S. deal tables — what raised, at what stage, and what founders should do next. Links to the live fund tracker.